111 related articles for article (PubMed ID: 8477804)
1. Structural motifs involved in human IgG antibody effector functions.
Greenwood J; Clark M; Waldmann H
Eur J Immunol; 1993 May; 23(5):1098-104. PubMed ID: 8477804
[TBL] [Abstract][Full Text] [Related]
2. Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis.
Greenwood J; Gorman SD; Routledge EG; Lloyd IS; Waldmann H
Ther Immunol; 1994 Oct; 1(5):247-55. PubMed ID: 7584499
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activities of OX40 (CD134)-IgG fusion protein isoforms with different levels of immune-effector functions.
Taylor L; Bachler M; Duncan I; Keen S; Fallon R; Mair C; McDonald TT; Schwarz H
J Leukoc Biol; 2002 Sep; 72(3):522-9. PubMed ID: 12223520
[TBL] [Abstract][Full Text] [Related]
4. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
5. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.
Natsume A; In M; Takamura H; Nakagawa T; Shimizu Y; Kitajima K; Wakitani M; Ohta S; Satoh M; Shitara K; Niwa R
Cancer Res; 2008 May; 68(10):3863-72. PubMed ID: 18483271
[TBL] [Abstract][Full Text] [Related]
6. Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge.
Norderhaug L; Brekke OH; Bremnes B; Sandin R; Aase A; Michaelsen TE; Sandlie I
Eur J Immunol; 1991 Oct; 21(10):2379-84. PubMed ID: 1915551
[TBL] [Abstract][Full Text] [Related]
7. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.
Gillies SD; Wesolowski JS
Hum Antibodies Hybridomas; 1990; 1(1):47-54. PubMed ID: 2129419
[TBL] [Abstract][Full Text] [Related]
8. The structural requirements for complement activation by IgG: does it hinge on the hinge?
Brekke OH; Michaelsen TE; Sandlie I
Immunol Today; 1995 Feb; 16(2):85-90. PubMed ID: 7888072
[TBL] [Abstract][Full Text] [Related]
9. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Morgan A; Jones ND; Nesbitt AM; Chaplin L; Bodmer MW; Emtage JS
Immunology; 1995 Oct; 86(2):319-24. PubMed ID: 7490135
[TBL] [Abstract][Full Text] [Related]
10. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
11. IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity.
Huang J; Shibaguchi H; Zhao J; Luo N; Kuroki M; Kinugasa T; Hirose Y; Yamada H; Kuroki M
Anticancer Res; 2006; 26(2A):1057-63. PubMed ID: 16619506
[TBL] [Abstract][Full Text] [Related]
12. A genetically engineered human IgG mutant with enhanced cytolytic activity.
Shopes B
J Immunol; 1992 May; 148(9):2918-22. PubMed ID: 1573276
[TBL] [Abstract][Full Text] [Related]
13. Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4.
Smith RI; Coloma MJ; Morrison SL
J Immunol; 1995 Mar; 154(5):2226-36. PubMed ID: 7868896
[TBL] [Abstract][Full Text] [Related]
14. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential.
Isaacs JD; Clark MR; Greenwood J; Waldmann H
J Immunol; 1992 May; 148(10):3062-71. PubMed ID: 1578132
[TBL] [Abstract][Full Text] [Related]
15. Activation of complement by an IgG molecule without a genetic hinge.
Brekke OH; Michaelsen TE; Sandin R; Sandlie I
Nature; 1993 Jun; 363(6430):628-30. PubMed ID: 8510754
[TBL] [Abstract][Full Text] [Related]
16. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
Niwa R; Natsume A; Uehara A; Wakitani M; Iida S; Uchida K; Satoh M; Shitara K
J Immunol Methods; 2005 Nov; 306(1-2):151-60. PubMed ID: 16219319
[TBL] [Abstract][Full Text] [Related]
17. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Woodhouse CS; Morgan AC
Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
[TBL] [Abstract][Full Text] [Related]
18. Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences.
Sibéril S; Dutertre CA; Boix C; Bonnin E; Ménez R; Stura E; Jorieux S; Fridman WH; Teillaud JL
Immunol Lett; 2006 Aug; 106(2):111-8. PubMed ID: 16797726
[TBL] [Abstract][Full Text] [Related]
19. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains.
Staelens S; Desmet J; Ngo TH; Vauterin S; Pareyn I; Barbeaux P; Van Rompaey I; Stassen JM; Deckmyn H; Vanhoorelbeke K
Mol Immunol; 2006 Mar; 43(8):1243-57. PubMed ID: 16118019
[TBL] [Abstract][Full Text] [Related]
20. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
